Comparative Pharmacology
Head-to-head clinical analysis: OBESTIN 30 versus PLEGINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OBESTIN 30 versus PLEGINE.
OBESTIN-30 vs PLEGINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ObesTin-30 is a selective serotonin reuptake inhibitor (SSRI) that blocks serotonin reuptake, increasing serotonin levels in the synaptic cleft, which modulates appetite and mood.
Plegine (phendimetrazine) is a sympathomimetic amine that acts as an anorectic agent. It stimulates the hypothalamus to release norepinephrine and dopamine, thereby suppressing appetite. The exact mechanism is thought to involve the release of catecholamines from presynaptic nerve terminals in the lateral hypothalamic feeding center, leading to decreased food intake.
30 mg subcutaneously once daily.
25-50 mg orally once daily at bedtime, maximum 100 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in patients with normal renal function; half-life may be prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 4–8 hours (mean 6 hours). Clinical context: Steady-state achieved after 24–48 hours of repeated dosing.
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose; fecal elimination via biliary excretion accounts for approximately 30%, with the remainder as metabolites.
Renal: 40% unchanged; Hepatic metabolism: 60% (biliary/fecal elimination of metabolites).
Category C
Category C
Anorexiant
Anorexiant